Physician profile
Janey Watts
NPI 1275885832
$4,708.49
in general payments reported to CMS, 2019-2025
33 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $236 · 2021: $843 · 2022: $2,160 · 2023: $410 · 2024: $466 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.00 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,423.58 | 2022-2024 | Minimed 780g |
| Abbvie INC. | $1,095.27 | 2019-2025 | Qulipta, Ubrelvy, Lo Loestrin Fe |
| Daiichi Sankyo INC. | $468.19 | 2019-2024 | Injectafer |
| Mayne Pharma Commercial LLC | $376.18 | 2021 | |
| Ani Pharmaceuticals, INC. | $137.71 | 2024-2025 | Purified Cortrophin Gel |
| Allergan, INC. | $125.08 | 2020 | |
| Lilly USA, LLC | $83.61 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $80.05 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $74.83 | 2022 | |
| Shield Therapeutics INC | $74.03 | 2024-2025 | |
| Glaxosmithkline, LLC. | $60.56 | 2022-2023 | Trelegy Ellipta, Bexsero |
| Myovant Sciences INC. | $57.08 | 2022 | |
| Sumitomo Pharma America, INC. | $57.02 | 2023-2024 | Myfembree |
| Exeltis, USA INC. | $51.37 | 2022-2023 | Nuvessa |
| Biohaven Pharmaceuticals, INC. | $49.47 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $48.99 | 2019-2024 | |
| Sobi, INC | $40.59 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $40.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.81 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.13 | 2022-2025 | |
| Abbott Laboratories | $33.22 | 2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $32.37 | 2022-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.37 | 2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $30.36 | 2024 | Dupixent |
| Merck Sharp & Dohme LLC | $26.70 | 2022-2024 | Vaxelis, Gardasil, Capvaxive |
| Boston Scientific Corporation | $23.50 | 2022 | |
| Amgen INC. | $20.80 | 2022 | |
| Gynesonics, INC. | $18.71 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Tris Pharma INC | $18.26 | 2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $16.07 | 2025 | Auvelity |
| Bausch Health US, LLC | $15.39 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.51 | 2019 | |
| Sage Therapeutics, LLC | $14.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janey Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.